Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Oct;25(10):1325-1336.
doi: 10.1016/S1470-2045(24)00389-9. Epub 2024 Sep 13.

Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study

Othon Iliopoulos  1 , Ane B Iversen  2 , Vivek Narayan  3 , Benjamin L Maughan  4 , Kathryn E Beckermann  5 , Stephane Oudard  6 , Tobias Else  7 , Jodi K Maranchie  8 , Cynthia Muller Goldberg  9 , Wei Fu  9 , Rodolfo F Perini  9 , Yanfang Liu  9 , W Marston Linehan  10 , Ramaprasad Srinivasan  10 , Eric Jonasch  11
Affiliations
Clinical Trial

Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study

Othon Iliopoulos et al. Lancet Oncol. 2024 Oct.

Erratum in

Abstract

Background: The first-in-class hypoxia-inducible factor-2α inhibitor, belzutifan, showed clinically meaningful antitumour activity in von Hippel-Lindau (VHL) disease-associated neoplasms in the ongoing, single-arm, phase 2 LITESPARK-004 study. We aimed to investigate antitumour activity with an additional 16 months of follow-up and present updated results for the subgroup of patients with CNS haemangioblastomas.

Methods: In the multicentre, single-arm, phase 2 LITESPARK-004 study, adults (aged ≥18 years) from 11 cancer centres or hospitals in the USA, Denmark, France, and the UK, with germline VHL alterations, at least one measurable renal cell carcinoma tumour, no renal cell carcinoma tumour greater than 3 cm requiring immediate surgical intervention, an Eastern Cooperative Oncology Group performance status 0 or 1, and no previous systemic therapy received oral belzutifan 120 mg once daily until unacceptable toxicity, disease progression, or patient decision to withdraw. The primary endpoint, evaluated in patients with CNS haemangioblastomas, was the proportion of patients with an objective response per RECIST version 1.1 by an independent review committee. We assessed response using two approaches. In approach 1, we evaluated all measurable (≥1 cm maximum diameter) or non-measurable lesions at baseline, including both the solid lesion and the associated cystic component if present. In approach 2, we evaluated only baseline lesions with a measurable (≥1 cm maximum diameter) solid lesion. Antitumour activity was assessed in all patients who received at least one dose of belzutifan. This study is no longer recruiting but is ongoing, and is registered with Clinicaltrials.gov, NCT03401788.

Findings: Between May 31, 2018, and March 29, 2019, of 67 patients screened, 61 (32 [52%] male and 29 [48%] female) were enrolled; 50 (82%) had at least one CNS haemangioblastoma evaluable at baseline (184 total lesions). Median follow-up for the 50 patients with CNS haemangioblastomas was 38·0 months (IQR 36·7-40·1). In approach 1, 22 of 50 patients (44% [95% CI 30-59]) had an objective response. In approach 2, 19 of 25 patients (76% [55-91] had an objective response. 23 (46%) of 50 patients had a grade 3-5 all-cause adverse event. 19 (38%) patients reported grade 3 adverse events, the most common of which was anaemia (in 6 [12%] patients). Two of 50 patients (4%) reported grade 4 events (retinal vein occlusion and embolism). Two patients died owing to adverse events not considered treatment-related (suicide and toxicity to various agents).

Interpretation: Belzutifan showed meaningful antitumour activity in VHL disease-associated CNS haemangioblastomas that was sustained for more than 3 years of treatment. These results continue to support belzutifan as a systemic treatment option for patients with VHL disease-related CNS haemangioblastomas.

Funding: Merck Sharp & Dohme, National Institutes of Health, and National Cancer Institute.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests VN has received support (to his institution) for the present manuscript from Merck; consulting fees from Bristol Myers Squibb, Exelixis, Janssen, Regeneron, and Eisai; honoraria from Pfizer; has participated on advisory boards for Myovant; and has received research support (to his institution) from Bristol Myers Squibb, Janssen, Merck, Rahway, NJ, USA, Pfizer, and Regeneron. BLM has received research funding (to his institution) from Exelixis, Bavarian-Nordic, Clovis, and Bristol Myers Squibb; and consulting fees from AbbVie, Pfizer, AVEO Oncology, Janssen, Astellas, Bristol Myers Squibb, Clovis, Tempus, Merck, Exelixis, Bayer Oncology, Lilly, Sanofi, Telix, and Peloton Therapeutics. KEB has received support for the present manuscript from Merck for provision of study drug and funding to her institution; has received the Young Investigator Award for correlative science from same clinical trial (to her institution), from BMS-IASLC-LCFA; has received funding for translational research (to her institution) from Aravive, Pionyr, and ArsenalBio; and has received consulting fees from Aravive, Alpine Bioscience, Aveo, AstraZeneca, Eisai, Exelixis, Bristol Myers Squibb, Merck, Nimbus, Sanofi, and Seagen. SO has received research funding (to his institution) from Bristol Myers Squibb, Sanofi, and AstraZeneca; consulting fees from Bristol Myers Squibb, Sanofi, Pfizer, Novartis, Janssen, Astellas, Bayer, and Ipsen; honoraria from Bristol Myers Squibb, Sanofi, Novartis, Janssen, Astellas, Bayer, and Ipsen; travel support from Janssen, Ipsen, and Bayer; and has participated on advisory boards for Roche, Ipsen, Pfizer, Bayer, and Janssen. TE has received support (to his institution) for the present manuscript from Merck; and consulting fees for advisory boards from Merck and Lanthaeus. JKM has received contracts for editorial services from Elsevier; honoraria from the Large Urology Group Practice Association; and travel support from the Kidney Cancer Association and Kidney Cancer Research Symposium. CMG is an employee of Merck Sharp & Dohme, a subsidiary of Merck (Rahway, NJ, USA), and has stock ownership in Merck. WF is an employee of Merck Sharp & Dohme, a subsidiary of Merck, and has stock ownership in Merck. RFP is an employee of Merck Sharp & Dohme, a subsidiary of Merck, and has stock ownership in Merck. YL is an employee of Merck Sharp & Dohme, a subsidiary of Merck, and has stock ownership in Merck. RS has received support for the present manuscript from Merck and Peloton; received drugs to do the studies and funds from the National Cancer Institute to partially cover the costs of doing the study at the National Institutes of Health from NiKang; received investigational agents for an investigator-initiated study under a CRADA with the National Cancer Institute from Pfizer; was primary investigator for an investigator-initiated trial where trial agents were provided by Genentech, and on an investigator-initiated trial where investigational agents were provided by Novartis. EJ has received research funding (to his institution) from Arrowhead, Merck, NiKang, andNovartis; consulting fees from Aveo, Eisai, Exelixis, Ipsen, Merck, and NiKang; honoraria from DAVA; participated on an advisory board for Novartis; and has a leadership role at the National Comprehensive Cancer Network. OI, ABI, and WML declare no competing interests.

Figures

Figure 1:
Figure 1:. Trial profile
RCC, renal cell carcinoma.
Figure 2:
Figure 2:. CNS hemangioblastomas with solid and cystic components (N = 50). (A) Duration of treatment and best response, (B) progression-free survival, (C) and best percentage change from baseline in CNS hemangioblastoma target lesionsa
CNS, central nervous system; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease. a30 patients had measurable disease at baseline.
Figure 3:
Figure 3:. CNS hemangioblastomas with solid lesions only (n = 25). (A) Duration of treatment and best response, (B) progression-free survival, and (C) best percentage change from baseline in CNS hemangioblastoma target lesions
CNS, central nervous system; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.
See this image and copyright information in PMC

Comment in

References

    1. Varshney N, Kebede AA, Owusu-Dapaah H, Lather J, Kaushik M, Bhullar JS. A review of Von Hippel-Lindau syndrome. J Kidney Cancer VHL 2017; 4(3): 20–9. - PMC - PubMed
    1. Ganeshan D, Menias CO, Pickhardt PJ, et al. Tumors in von Hippel-Lindau syndrome: from head to toe-comprehensive state-of-the-art review. Radiographics 2018; 38(3): 849–66. - PubMed
    1. Kanno H, Kobayashi N, Nakanowatari S. Pathological and clinical features and management of central nervous system hemangioblastomas in von Hippel-Lindau disease. J Kidney Cancer VHL 2014; 1(4): 46–55. - PMC - PubMed
    1. Klingler JH, Gläsker S, Bausch B, et al. Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment. Childs Nerv Syst 2020; 36(10): 2537–52. - PMC - PubMed
    1. Chittiboina P, Lonser RR. Von Hippel-Lindau disease. Handb Clin Neurol 2015; 132: 139–56. - PMC - PubMed

Publication types

MeSH terms

Substances

Associated data